<DOC>
	<DOCNO>NCT02521649</DOCNO>
	<brief_summary>An open , dose-ranging , multiple dose , multi-centre study patient Stage I-III Stage IV gastric cancer . Twelve patient 5 treatment group receive three injection week 0 , 2 6 provision single booster injection extension study period .</brief_summary>
	<brief_title>Dose-ranging Study Evaluate Antibody Response G17DT Patients With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Stage IIII Criteria Patients age 18 year macroscopically curative resection gastric adenocarcinoma . Absence metastatic disease evident : physical examination recent chest Xray abdominal CT ultrasound scan Life expectancy least 3 month WHO performance status 0 1 Written informed consent give Stage IV Criteria Patients age 18 year Stage IV gastric cancer : carcinoma primary tumour invade adjacent structure and/or involvement 15 regional lymph node and/or distant metastasis Life expectancy least 3 month WHO performance status 0 2 Written informed consent give History malignant disease except nonmelanomatous skin cancer situ carcinoma uterine cervix Recurrent gastric cancer follow previous surgery Presence metastatic disease : peritoneal deposit involve lymph node outside limit resection Previous use , concomitant use anticipate use period study , anticancer therapy Concomitant use immunosuppressant , include systemic ( ie oral inject ) corticosteroid Females pregnant , plan become pregnant lactating Patients take part another study involve investigational license drug device three month precede enrolment study Previous G17DT treatment Haematological indicator : Haemoglobin &lt; 10.0g/dl White blood cell count &lt; 4.0 x 109/l Platelets &lt; 100 x 109/l</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>G17DT</keyword>
	<keyword>PAS</keyword>
	<keyword>Insegia</keyword>
	<keyword>Gastrimmune</keyword>
</DOC>